Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Evolocumab on Major Cardiovascular Events in High-Risk Patients Without Prior MI or Stroke
2018-004565-14Phase 3Active
- Sponsor
- Amgen
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, cardiac morbidity, coronary arteriosclerosis and 1 more comparing Evolocumab arm with Placebo arm (2 arms). Started Mar 2019; status: active.
02
Drugs
evolocumab
03
Conditions
dyslipidemiacardiac morbiditycoronary arteriosclerosisischemic stroke
Beyond the preview
Go deeper on 2018-004565-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004565-14.